Amisodin safety study for healthy adults with ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a new drug called Amisodin in healthy adults who also have ALS. It checks if the drug is safe and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old
- You are a healthy adult with ALS
- You are a non-smoker for at least 3 months
- Your BMI is between 18.0 and 32.0
- You are not pregnant and can follow birth control rules if male
- You have no major medical conditions or drug allergies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called BIIB147 to see if it is safe and to learn how it affects people with ALS. It may help slow the progression of the disease.
This trial tests a medication called darifenacin (usually used for bladder problems) in people with ALS, to see if it is safe and if it might help slow the disease. If you join, you will take the study drug or a placebo and be closely monitored.
This trial tests a new drug called TP04HN106 for people with ALS. It aims to see if it is safe and if it might slow down the disease. You may qualify if your breathing is still fairly good and you have been on a stable dose of riluzole.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
This trial tests a new drug, RAG-17, for people with ALS who have a specific SOD1 gene mutation. The goal is to see if it's safe and how it affects the body, which may help slow the disease.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.